Treats elevated intraocular pressure. ANDA 78395, held by Rubicon Research. Dorzolamide Hydrochloride.
As of Nov 16, 2026, ANDA 78395 (Dorzolamide Hydrochloride), held by Rubicon Research, was first approved by FDA on Oct 28, 2008, with 3 approved supplements and 0 published complete response letters.
Dorzolamide hydrochloride ophthalmic solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Dorzolamide hydrochloride is a carbonic anhydrase inhibitor indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 28, 2008 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Dorzolamide HydrochlorideEQ 2% BASE · solution/drops;ophthalmic | Dorzolamide Hydrochloride | Rx |
| Dec 3, 2021 | Supplement 10Labeling · Standard review | Approved | None posted |
| Nov 27, 2015 | Supplement 8Labeling · Standard review | Approved | None posted |
| Jan 28, 2011 | Supplement 4Labeling | Approved | None posted |
| Oct 28, 2008 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters